Joao Cavalcante, MD, of the Minneapolis Heart Institute, discusses new structural heart interventions to treat tricuspid valve regurgitation.

Pulmonary artery denervation may offer a new therapy option for this difficult-to-treat population.

Two late-breaking studies at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) meeting provided positive data for Abbott's MitraClip transcatheter mitral valve repair (TMVR) device and the TriClip for transcatheter tricuspid valve repair (TTVR).

Hear from Dr. Nicholas T. Skipitaris on how to improve overall department efficiencies, freeing up physicians to spend more time with their patients.

The FDA granted the first pediatric indication for an implantable cardiac monitor. The Linq II can be used in pediatric patients over the age of 2 for up to 4.5 years of long-term, continuous monitoring. 

Comparison between transcatheter edge-to-edge repair (TEER) devices found Pascal was non-inferior compared with MitraClip in the CLASP IID pivotal trial.

The UNIVERSAL Trial, one of the largest multicenter randomized trials comparing ultrasound with fluoroscopic guidance vs. fluoroscopic guidance alone, found there was no reduction in major vascular access complications. 

The American Hospital Association (AHA) and the American Medical Association (AMA) have dropped their legal challenge to the interim final rule independent dispute resolution process of the No Surprises Act.

UnitedHealth Group can move ahead with its planned $13 billion acquisition of Change Healthcare after a district court shot down the Department of Justice’s attempt to block the transaction.

Despite higher rates of burnout and stress among healthcare workers during the pandemic, the healthcare industry has reported lower unemployment rates than other fields.

Insured or not, few Americans are immune to medical debt. And when a budget-busting event comes, it can significantly worsen such basic social determinants of health (SDOH) as housing security and food affordability.